KR20180091311A - Composition for Respiratory Symptoms Containing Red Ginseng Extract - Google Patents
Composition for Respiratory Symptoms Containing Red Ginseng Extract Download PDFInfo
- Publication number
- KR20180091311A KR20180091311A KR1020170016296A KR20170016296A KR20180091311A KR 20180091311 A KR20180091311 A KR 20180091311A KR 1020170016296 A KR1020170016296 A KR 1020170016296A KR 20170016296 A KR20170016296 A KR 20170016296A KR 20180091311 A KR20180091311 A KR 20180091311A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- neck
- symptoms
- red ginseng
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 86
- 208000024891 symptom Diseases 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 33
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 23
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 10
- 241001105098 Angelica keiskei Species 0.000 claims description 6
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 6
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 241000125175 Angelica Species 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 12
- 235000013402 health food Nutrition 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 240000001810 Angelica gigas Species 0.000 abstract description 4
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 abstract description 2
- 241001532026 Liriope muscari Species 0.000 abstract description 2
- 241000949731 Ulmus davidiana Species 0.000 abstract description 2
- 244000067505 Xanthium strumarium Species 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 description 22
- 235000008504 concentrate Nutrition 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 19
- 235000019640 taste Nutrition 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000003800 pharynx Anatomy 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 244000061520 Angelica archangelica Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 240000004371 Panax ginseng Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000000621 bronchi Anatomy 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028836 Neck pain Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- -1 olive oil Chemical compound 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000021663 Female sexual arousal disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000002045 Guettarda speciosa Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006429 Bronchial conditions Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- PSUBPFRWJHQJIA-UHFFFAOYSA-K [Ca+2].C(C=CC=CC)(=O)[O-].[Na+].C(C=CC=CC)(=O)[O-].C(C=CC=CC)(=O)[O-] Chemical compound [Ca+2].C(C=CC=CC)(=O)[O-].[Na+].C(C=CC=CC)(=O)[O-].C(C=CC=CC)(=O)[O-] PSUBPFRWJHQJIA-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 244000261228 chanvre indien Species 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229940117383 elder extract Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 홍삼 추출물을 함유하는 호흡기 증상 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving respiratory symptoms containing red ginseng extract.
호흡기는 호흡에 관련된 기관을 총칭하며, 비강, 인두, 후두, 기관, 기관지, 폐를 포함한다. 목과 기관지는 여러 가지 이유로 답답해지거나, 따끔거리는 등의 증상이 나타난다. 주요 원인으로는 과로, 피로, 황사, 환절기와 같은 급격한 날씨 변화 등이 있다. 기관지 질환의 경우 수면을 방해하고, 생활 환경에 따라 알레르기성 질환으로 심화되는 경우가 많기 때문에 증상이 나타났을 때 조기에 개선하는 것이 바람직하다. 통상적으로 목의 통증은 코와, 전신의 피로감이 병행되기 때문에 목의 통증을 완화하면서도 피로감을 해소할 수 있는 원료에 대한 연구가 필요한 실정이다. The respiratory tract is collectively referred to the respiratory organs and includes the nasal cavity, pharynx, larynx, trachea, bronchus and lung. Throat and bronchial pains appear to be ugly or stingy for a variety of reasons. Major causes include overwork, fatigue, yellow dust, and sudden weather changes such as the season of change. In the case of bronchial diseases, it is desirable to improve early when symptoms appear because it interferes with sleeping and becomes more severe as an allergic disease depending on the living environment. In general, neck pain is accompanied by nose and general fatigue, so it is necessary to study the raw materials that can alleviate the pain of the neck while relieving fatigue.
호흡기 질환을 치료하는 예로서, 특허문헌 1에는 호흡기 질환을 치료하기 위해서 포도상구균(Staphylococcus), 모라셀라(Moraxella), 크렙시엘라( Klebsiella), 연쇄상구균(Streptococcus), 및 헤모필루스(Haemophilus) 등의 박테리아 균주(bacterial strains) 유래 추출물을 이용하는 기술이 개시되어 있다. 또한, 목의 통증을 해소하기 위해서 기존에 무나, 배 등을 끓여서 먹는 전통 치료 요법이 있었다. 하지만, 사람마다 치료 개선 정도에 차이가 있어서, 목 통증에 대한 개선 효과가 우수하면서도 많은 사람들에게서도 동일한 효과를 보이는 원료에 대해서 연구가 필요하였다.As an example of treating respiratory diseases, Patent Document 1 discloses a method for treating respiratory diseases such as Staphylococcus, Moraxella, Klebsiella, Streptococcus, and Haemophilus Techniques using bacterial strains derived extracts have been disclosed. In addition, to relieve the pain of the neck, traditional treatments were to boil muna and boats. However, there was a difference in the degree of improvement in treatment for each person, and research was needed on the raw materials showing the same effect on many people, although the improvement on the neck pain was excellent.
인삼은 오가피과 인삼속의 한방 약제이며, 홍삼은 인삼의 뿌리를 쪄서 말리는 방법에 의해 제조된다. 인삼은 아미노산, 비타민, 유기산, 탄수화물, 각종 광물질을 포함하고 있어 강장 작용, 갈증 해소, 면역 기능 강화, 혈압, 당뇨, 각종 질병을 예방하고 치료하는데 뛰어난 효과를 가진 약초로 알려져 있다. Ginseng is a herb medicine in ginseng and ginseng, and red ginseng is produced by steaming and drying ginseng roots. Ginseng contains amino acids, vitamins, organic acids, carbohydrates and various minerals. It is known as an excellent herb to prevent and cure tonic effects, relieve thirst, strengthen immune function, blood pressure, diabetes and various diseases.
본 발명자들은 홍삼과 한약재를 포함하는 조성물이 목의 답답함, 건조함, 칼칼함 등을 개선할 수 있는지 연구하였으며, 홍삼, 당귀, 맥문동, 황기, 창이자 및 유근피를 포함하는 조성물이 흡연자, 비흡연자, 노약자 모두에서 목의 통증을 개선하면서도 피로감을 회복하는 효과를 나타내는 것을 확인하였다. The present inventors have studied whether compositions containing red ginseng and herbal medicines can improve the frigidity of the neck, dryness, chalking, and the like. The composition containing red ginseng, angelica gigantis, mangmundong, hwanggi, It was confirmed that the effect of restoring fatigue was improved while improving neck pain in all.
본 발명은 호흡기 증상을 개선하기 위한 조성물을 제공하는 것을 과제로 한다.It is an object of the present invention to provide a composition for improving respiratory symptoms.
상기 과제를 해결하기 위하여, 본 발명은 홍삼 추출물, 당귀 추출물, 맥문동 추출물, 황기 추출물, 창이자 추출물 및 유근피 추출물로 이루어진 혼합 추출물을 포함하는 호흡기 증상 예방 또는 치료용 약학적 조성물을 제공한다.In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating respiratory symptoms, which comprises a mixed extract of red ginseng extract, angelica gigantis extract, mungumun dong extract, hwanggi extract, ganoderma extract and rhizome extract.
또한, 본 발명은 홍삼 추출물, 당귀 추출물, 맥문동 추출물, 황기 추출물, 창이자 추출물 및 유근피 추출물로 이루어진 혼합 추출물을 포함하는 호흡기 증상 개선용 건강 식품 조성물을 제공한다.In addition, the present invention provides a health food composition for improving respiratory symptoms, comprising a mixed extract of red ginseng extract, angelica guinea extract, mungumun dong extract, hwanggi extract, chrysanthemum extract and rhizome extract.
본 발명의 호흡기 증상 개선용 조성물은 목의 답답함, 건조함, 칼칼함과 같은 증상을 개선하는 효과가 있다. The composition for improving respiratory symptoms of the present invention has the effect of improving symptoms such as dryness, dryness, and chalking of the neck.
도 1은 본 발명의 호흡기 증상 개선용 조성물 섭취 후의 전반적인 목 건강 상태를 나타낸다.
도 2는 본 발명의 호흡기 증상 개선용 조성물 섭취 후의 목/기관지 관련 증상 개선 정도를 나타낸다.
도 3은 본 발명의 호흡기 증상 개선용 조성물 섭취 후의 목/기관지 관련 증상 개선율을 나타낸다.
도 4는 본 발명의 호흡기 증상 개선용 조성물 섭취 후의 비흡연자군에 대한 증상별 개선 정도 및 개선율 정도를 나타낸다.
도 5는 본 발명의 호흡기 증상 개선용 조성물 섭취 후의 흡연자군에 대한 증상별 개선 정도 및 개선율 정도를 나타낸다.
도 6은 본 발명의 호흡기 증상 개선용 조성물 섭취 후의 노약자군에 대한 증상별 개선 정도 및 개선율 정도를 나타낸다.Fig. 1 shows the overall neck condition after ingestion of the composition for improving respiratory symptoms of the present invention.
Fig. 2 shows the degree of improvement of the neck / bronchial related symptoms after ingesting the composition for improving respiratory symptoms of the present invention.
FIG. 3 shows the improvement rate of neck / bronchial-related symptoms after ingesting the composition for improving respiratory symptoms of the present invention.
FIG. 4 shows the degree of improvement and the degree of improvement according to the symptoms of the non-smokers after ingesting the composition for improving respiratory symptoms of the present invention.
FIG. 5 shows the degree of improvement and the degree of improvement according to symptoms of smokers after intake of the composition for improving respiratory symptoms of the present invention.
FIG. 6 shows the degree of improvement and the degree of improvement of symptoms for the elderly group after ingestion of the composition for improving respiratory symptoms of the present invention.
먼저, 본 발명에서 사용된 용어에 대해서 설명한다.First, terms used in the present invention will be described.
본 명세서에서 사용된 "예방"이라 함은 호흡기 증상을 방지하는 것을 의미하며, 방지, 치료, 완화 등을 포함하는 넓은 개념으로 이해될 수 있다.As used herein, the term " prevention " means prevention of respiratory symptoms and can be understood as a broad concept including prevention, treatment, mitigation and the like.
본 명세서에서 사용된 "개선"은 호흡기 증상을 치료하여 원래의 상태에 가깝도록 회복시키는 것을 의미하는 넓은 개념으로 이해될 수 있다."Improvement ", as used herein, can be understood as a broad concept which means treating respiratory symptoms and restoring them to their original state.
본 명세서에서 사용된 "호흡기 증상"은 호흡기에 나타나는 통증이나 이물감을 나타내며, 호흡기에 포함되는 코, 목, 부비동, 기관지, 폐에 나타나는 이상 증상을 모두 포함하는 개념으로 이해될 수 있다.The term " respiratory symptom "used herein refers to a pain or foreign body sensation appearing in the respiratory tract and can be understood as including all the abnormal symptoms appearing in the nose, throat, sinus, bronchus and lung included in the respiratory system.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 홍삼 추출물, 당귀 추출물, 맥문동 추출물, 황기 추출물, 창이자 추출물 및 유근피 추출물로 이루어진 혼합 추출물을 포함하는 호흡기 증상 예방 또는 치료용 약학적 조성물을 제공한다. The present invention provides a pharmaceutical composition for preventing or treating respiratory symptoms, which comprises a mixed extract of red ginseng extract, angelica gigantis extract, mungmun dong extract, hwanggi extract, chrysanthemum extract and rhizome extract.
상기 추출물은 원료 또는 이의 건조물로부터 추출하여 얻을 수 있으며, 상기 원료는 재배한 것 또는 시판되는 것 등을 제한 없이 사용할 수 있다.The extract may be obtained by extracting from a raw material or a dried product thereof, and the raw material may be cultivated or commercially available.
상기 추출물을 원료로부터 추출하여 수득할 때, 추출 방법으로는 용매 추출법, 초음파 추출법, 여과법 및 환류 추출법 등 종래 알려진 통상적인 추출 방법을 모두 사용할 수 있으며, 바람직하게는 용매 추출법이나 환류 추출법을 이용함으로써 제조할 수 있다. 상기 추출 과정은 수회 반복할 수 있으며, 이후에 농축 또는 동결건조 등의 단계를 추가적으로 거칠 수 있다. 구체적으로, 수득한 추출물을 감압 농축하여 농축액을 얻고, 상기 농축액을 동결건조시킨 후 분쇄기를 이용하여 고농도의 추출 분말을 제조할 수 있다.When the extract is obtained by extracting from the raw material, any conventional extraction methods known in the art such as a solvent extraction method, an ultrasonic extraction method, a filtration method and a reflux extraction method may be used as the extraction method. Preferably, the extraction method or the reflux extraction method can do. The extraction process can be repeated several times, and then the step such as concentration or freeze-drying can be further roughened. Specifically, the obtained extract is concentrated under reduced pressure to obtain a concentrated liquid, the concentrated liquid is lyophilized, and a concentrated powder can be produced using a pulverizer.
상기 추출물은 물, 유기용매 또는 이들의 혼합물을 추출용매로 하여 추출될 수 있다. 상기 유기용매는 알코올, 바람직하게는 C1-C4의 알코올, 헥산(n-헥산), 에테르, 글리세롤, 프로필렌글리콜, 부틸렌글리콜, 에틸아세테이트, 메틸아세테이트, 디클로로메탄, 클로로포름, 에틸아세테이트, 벤젠 및 이들의 혼합용매일 수 있다.The extract can be extracted with water, an organic solvent or a mixture thereof as an extraction solvent. The organic solvent may be at least one selected from the group consisting of alcohols, preferably C 1 -C 4 alcohols, hexane (n-hexane), ether, glycerol, propylene glycol, butylene glycol, ethyl acetate, methyl acetate, dichloromethane, chloroform, ethyl acetate, Lt; / RTI >
상기 혼합 추출물은 홍삼, 당귀, 맥문동, 황기, 창이자 및 유근피의 혼합물을 추출할 수도 있고, 각 원료로부터 추출물을 수득한 후에 혼합할 수도 있으나, 이에 한정되는 것은 아니다.The above-mentioned mixed extract may be a mixture of red ginseng, angelica gingiva, ginseng, mulberry, hwanggi, ganja, and yugi, or may be mixed after obtaining an extract from each raw material.
상기 홍삼 추출물 1 내지 20중량부에 대해서, 당귀 추출물은 0.6 내지 0.1중량부로, 맥문동 추출물은 0.6 내지 0.1중량부로, 황기 추출물은 1.0 내지 0.3중량부로, 창이자 추출물은 0.6 내지 0.1중량부로, 유근피 추출물은 0.6 내지 0.1중량부로 포함될 수 있다. 하한값 미만으로 포함될 경우에는 호흡기 증상이 개선되지 않을 수 있고, 상한값을 초과하여 포함될 경우에는 조성물의 맛이 변해, 예를 들면 쓴맛이 강해지거나, 목 넘김이 부드럽지 않아 섭취가 쉽지 않다.The extract of Angelica keiskei koidz. Extract is used in an amount of 0.6 to 0.1 parts by weight, the extract of Angelica keiskei koidzaiensis extract is used in an amount of 0.6 to 0.1 parts by weight, 0.6 to 0.1 part by weight. If it is contained below the lower limit value, the respiratory symptoms may not be improved. If it exceeds the upper limit value, the taste of the composition changes, for example, the bitter taste becomes stronger or the neck turn is not smooth.
본 발명의 한 구현예에서는 홍삼 농축액을 6중량부로 포함하고, 당귀 농축액은 0.36중량부로, 맥문동 농축액은 0.36중량부로, 황기 농축액은 0.6중량부로, 창이자 농축액은 0.34중량부로, 유근피 농축액은 0.34중량부로 포함하는 조성물을 제조하고, 1달 동안 50㎖/1일씩 섭취한 결과, 호흡기 증상인 목의 답답함, 건조함, 칼칼함, 따끔거림과 같은 증상이 현저히 개선되는 것을 확인하였다(도 1 내지 도 6). In one embodiment of the present invention, the red ginseng concentrate is contained in an amount of 6 parts by weight, the Angelica gigantis concentrate is 0.36 parts by weight, the Mukumundong concentrate is 0.36 parts by weight, the Hwanggak concentrate is 0.6 part by weight, the Chrysantia concentrate is 0.34 part by weight, (1) to (6) of the present invention, the symptoms such as dryness, dryness, chalking and tingling of the neck, which is respiratory symptom, were remarkably improved as a result of ingesting 50 ml / .
호흡기 증상은 목의 답답함, 목의 건조함, 목의 칼칼함, 목 잠김 및 목의 따끔거림으로 이루어진 군으로부터 선택되는 어느 하나 이상일 수 있으나, 이에 한정되지 않는다. 본 발명의 조성물을 적용하여 개선될 수 있는 호흡기 증상으로는 편도(목)부음, (기침)재채기, 가래 끓음, 인후통, 목소리 갈라짐, 비염 등을 들 수 있다. Respiratory symptoms may include, but are not limited to, one or more selected from the group consisting of stiffness of the neck, dryness of the neck, sagging of the neck, throat and neck tingling. Examples of respiratory symptoms that can be improved by applying the composition of the present invention include one-shot (throat), cough (sneezing), boiling of the sputum, sore throat, vomiting and rhinitis.
본 발명의 조성물은 호흡기 증상을 개선 또는 치료하는 효과를 가지는 공지의 화합물 또는 추출물과 병행하여 섭취할 수 있다.The composition of the present invention may be ingested in combination with a known compound or extract having an effect of improving or treating respiratory symptoms.
본 발명에 따른 조성물의 섭취량은 10㎖/1일 내지 200㎖/1일 일 수 있고, 20㎖/1일 내지 170㎖/1일 일수 있고, 30㎖/1일 내지 150㎖/1일 일 수 있다. 하한값 미만으로 섭취할 경우에는 호흡기 증상이 개선되지 않을 수 있고, 상한값을 초과하여 섭취할 경우에는 본 발명의 조성물에 포함되는 한약재를 과량으로 섭취하게 되기 때문에 이에 따른 부작용이 발생할 수 있다.The amount of the composition according to the present invention may be 10 ml / day to 200 ml / day, 20 ml / day to 170 ml / day, 30 ml / day to 150 ml / have. In case of ingesting below the lower limit value, respiratory symptoms may not be improved. If ingested in excess of the upper limit value, the herbal medicines contained in the composition of the present invention are consumed in an excessive amount, which may cause side effects.
본 발명에 따른 조성물은 1일 내지 3개월 동안 섭취할 수 있고, 바람직하게는 15일 내지 1개월 동안 섭취할 수 있으나, 이에 한정하지 않으며, 증상의 개선을 위해서 장기적으로 섭취할 수 있다.The composition according to the present invention may be ingested for 1 to 3 months, preferably 15 to 1 month, but is not limited thereto and can be taken for a long term to improve symptoms.
본 발명의 한 구현예에서는 본 발명의 조성물을 1달 동안 50㎖/1일씩 섭취한 결과, 기관지 증상인 목의 답답함, 건조함, 칼칼함, 따끔거림과 같은 증상이 현저히 개선되는 것을 확인하였다(도 1 내지 도 6). In one embodiment of the present invention, the composition of the present invention was ingested at a dose of 50 ml / day for 1 month, and it was found that symptoms such as stiffness, dryness, dryness, and tingling of the neck of the bronchial symptom were remarkably improved 1 to 6).
본 발명의 약학적 조성물은 상기 혼합 추출물 외에 본 발명이 목적으로 하는 효과를 손상시키지 않는 범위 내에서, 바람직하게는 상기 혼합 추출물의 효과에 상승 효과를 줄 수 있는 다른 성분 등을 추가로 함유할 수 있다. 예를 들어 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 또는 담체를 포함할 수 있다.The pharmaceutical composition of the present invention may further contain, in addition to the above-mentioned mixed extract, other ingredients which can give a synergistic effect to the effect of the above-mentioned mixed extract within a range that does not impair the objective effect of the present invention have. For example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, or carriers.
상기 약학적 조성물의 투여 경로는 구강, 정맥내, 근육내, 동맥내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장이 포함되고, 예컨대 도포에 의한 국부투여(topical application) 방식으로 적용될 수 있다. 상기 비경구는 피하, 피내, 정맥내, 근육내, 병소내 주사 또는 주입기술을 포함한다. The route of administration of the pharmaceutical composition may be oral, intravenous, intramuscular, intraarterial, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal, for example topical application by application, . ≪ / RTI > The parenteral route includes subcutaneous, intradermal, intravenous, intramuscular, intralesional injection or infusion techniques.
상기 약학적 조성물은 상기 혼합 추출물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 상기 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition may contain at least one active ingredient which exhibits the same or similar function in addition to the mixed extract. The compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral preparations, external preparations, suppositories and sterilized injection solutions according to a conventional method.
경구투여를 위한 고형제제에는 산제, 과립제, 정제, 캡슐제, 연질캅셀제, 환 등이 포함된다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제로는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 멸균된 수용액, 액제, 비수성용제, 현탁제, 에멀젼, 시럽, 좌제, 에어로졸 등의 외용제 및 멸균 주사제제의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학적 조성물을 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Solid form preparations for oral administration include powders, granules, tablets, capsules, soft capsules, and the like. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. As the agent for parenteral administration, the external preparation such as powders, granules, tablets, capsules, sterilized aqueous solutions, liquid preparations, non-aqueous solutions, suspensions, emulsions, syrups, suppositories and aerosols, The composition may be formulated in the form of a cream, a gel, a patch, a spray, an ointment, a warning agent, a lotion, a liniment, a pasta or a cataplasma, , But is not limited thereto. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.
상기 조성물은 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 보조제, 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법인 혼합, 과립화 또는 코팅 방법에 따라 제형화할 수 있다.Such compositions may additionally contain preservatives, stabilizers, wettable or emulsifying accelerators, adjuvants such as salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances and may be prepared by conventional methods of mixing, It can be formulated according to the coating method.
상기 약학적 조성물의 투여량은 개체의 연령, 체중, 일반적인 건강, 성별, 투여시간, 투여 경로, 배출률, 약물 배합 및 특정 질환의 중증을 포함한 여러 요인에 따라 다양하게 변할 수 있다. 또한, 본 발명의 약학적 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다. 또한 상기 약학적 조성물은 성인 기준으로 0.001 내지 100㎎/㎏ 범위 내의 투여량으로 투여될 수 있고,상기 약학적 조성물이 외용제인 경우에는 성인기준으로 1.0 내지 3.0㎖의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속하는 것이 좋으나, 상기 투여량은 본 발명의 범위를 한정하는 것이 아니다.The dosage of the pharmaceutical composition may vary depending on various factors including the age, body weight, general health, sex, administration time, route of administration, rate of excretion, drug combination and severity of the specific disease. In addition, the pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers. The pharmaceutical composition may be administered at a dose within the range of 0.001 to 100 mg / kg on an adult basis. When the pharmaceutical composition is an external preparation, it may be administered once to 5 It is preferable to apply it for one month or longer, but the dose does not limit the scope of the present invention.
상기 약학적 조성물을 단위 용량 형태로 제형화하는 경우, 유효성분으로서 본 발명의 혼합 추출물은 약(0.01 내지 1,500)㎎의 단위 용량으로 함유되는 것이 바람직하고, 성인 치료에 필요한 투여량은 투여의 빈도와 강도에 따라 하루에 약(1 내지 500)㎎ 범위가 보통이나 이에 한정되는 것은 아니며, 일부 환자의 경우 더 높은 1일 투여량이 바람직할 수 있다.When the pharmaceutical composition is formulated in a unit dose form, it is preferable that the mixed extract of the present invention is contained as an active ingredient in a unit dose of about 0.01 to 1,500 mg, And a range of about (1 to 500) mg per day, depending on the strength, but is not limited thereto, and in some patients a higher daily dose may be desirable.
또한, 본 발명은 홍삼 추출물, 당귀 추출물, 맥문동 추출물, 황기 추출물, 창이자 추출물 및 유근피 추출물로 이루어진 혼합 추출물을 포함하는 호흡기 증상 개선용 건강 식품 조성물을 제공한다.In addition, the present invention provides a health food composition for improving respiratory symptoms, comprising a mixed extract of red ginseng extract, angelica guinea extract, mungumun dong extract, hwanggi extract, chrysanthemum extract and rhizome extract.
본 발명의 건강식품 조성물은 상기에 열거한 추출물을 포함하는 것 이외에, 건강을 개선시키는 효과가 있다고 알려진 공지의 천연물 또는 화합물을 추가로 포함할 수 있다.The health food composition of the present invention may further include known natural substances or compounds known to have health improving effects in addition to those enumerated above.
예컨대, 본 발명의 조성물에는 상기 혼합 추출물 이외에 감미제, 풍미제, 생리활성 성분, 미네랄, 가공보조제 등이 포함될 수 있다. For example, the composition of the present invention may contain a sweetener, a flavoring agent, a physiologically active ingredient, a mineral, a processing aid, and the like in addition to the mixed extract.
감미제는 식품이 적당한 단맛을 나게 하는 양으로 사용될 수 있으며, 천연 물이거나 합성된 것일 수 있다. 바람직하게는 천연 감미제를 사용하는 경우이고, 천연 감미제로는 옥수수 시럽 고형물, 꿀, 수크로오스, 프락토오스, 락토오스, 말토오스 등의 당 감미제를 들 수 있다.Sweeteners may be used in an amount such that the sweetness of the food is adequate and may be natural or synthetic. Preferably, natural sweeteners are used. Natural sweeteners include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.
풍미제는 맛이나 향을 좋게 하기 위하여 사용될 수 있으며, 천연물과 합성된 것 모두 사용될 수 있다. 바람직하게는 천연물을 사용하는 경우이다. 천연물을 사용할 경우에 풍미 이외에 영양 강화의 목적도 병행할 수 있다. 천연 풍미제로는 사과, 레몬, 감귤, 포도, 딸기, 복숭아 등에서 얻어진 것이거나 녹차잎, 둥굴레, 대잎, 계피, 국화 잎, 자스민 등에서 얻어진 것일 수 있다. 또 죽순, 알로에 베라, 은행 등에서 얻어진 것을 사용할 수 있다. 천연 풍미제는 액상의 농축액이나 고형상의 추출물일 수 있다. 경우에 따라서 합성 풍미제가 사용될 수 있는데, 합성 풍미제는 에스테르, 알코올, 알데하이드, 테르펜 등의 형태의 것들이 이용될 수 있다.Flavors may be used to improve taste or aroma, and may be used in combination with natural products. Preferably, a natural product is used. When natural products are used, nutritional fortification can be performed in addition to flavor. Natural flavors include those obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or those obtained from green tea leaves, Asiatica, Daegu, Cinnamon, Chrysanthemum leaves and Jasmine. Also, those obtained from bamboo shoots, aloe vera, banks and the like can be used. The natural flavoring agent may be a liquid concentrate or a solid form of extract. Synthetic flavoring agents may be used depending on the case, and synthetic flavoring agents such as esters, alcohols, aldehydes and terpenes may be used.
생리 활성 물질로는 카테킨, 에피카테킨, 갈로카테킨, 에피갈로카테킨 등의 카테킨류나, 레티놀, 아스코르브산, 토코페롤, 칼시페롤, 티아민, 리보플라빈 등의 비타민류 등이 사용될 수 있다.Examples of the physiologically active substance include catechins such as catechin, epicatechin, gallocatechin and epigallocatechin, and vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamin, and riboflavin.
미네랄로는 칼슘, 마그네슘, 크롬, 코발트, 구리, 불소화물, 게르마늄, 요오드, 철, 리튬, 마그네슘, 망간, 몰리브덴, 인, 칼륨, 셀레늄, 규소, 나트륨, 황, 바나듐, 아연 등이 사용될 수 있다.As the minerals, calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, .
또한 본 발명의 조성물은 상기 감미제 등 이외에도 필요에 따라 보존제, 유화제, 산미료 등을 포함할 수 있다.In addition, the composition of the present invention may contain a preservative, an emulsifying agent, an acidifier, and the like in addition to the above sweetener.
이러한 보존제, 유화제 등은 그것이 첨가되는 용도를 달성할 수 있는 한 극미량으로 첨가되어 사용되는 것이 바람직하다. 극미량이란 수치적으로 표현할 때 식품 조성물 전체 중량을 기준으로 할 때 0.0005중량% 내지 약 0.5중량% 범위를 의미한다. Such preservatives, emulsifiers and the like are preferably added in a very small amount as long as they can attain an application to which they are added. The term " trace amount " means, when expressed numerically, in the range of 0.0005% by weight to about 0.5% by weight based on the total weight of the food composition.
사용될 수 있는 보존제로는 나트륨 소르브산칼슘, 소르브산나트륨, 소르브산칼륨, 벤조산칼슘, 벤조산나트륨, 벤조산칼륨, EDTA(에틸렌디아민테트라아세트산) 등을 들 수 있다. Preservatives that can be used include calcium sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, and EDTA (ethylenediamine tetraacetic acid).
사용될 수 있는 유화제로는 아카시아검, 카르복시메틸셀룰로스, 잔탄검, 펙틴 등을 들 수 있다.Examples of the emulsifying agent that can be used include acacia gum, carboxymethyl cellulose, xanthan gum, pectin and the like.
사용될 수 있는 산미료로는 구연산, 말산(사과산), 푸마르산, 아디프산, 인산, 글루콘산, 타르타르산, 아스코르브산, 아세트산, 인산 등을 들 수 있다. 이러한 산미료는 맛을 증진시키는 목적 이외에 미생물의 증식을 억제할 목적으로 식품 조성물이 적정 산도가 되도록 첨가될 수 있다.Examples of the acidulant that can be used include citric acid, malic acid (malic acid), fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, and phosphoric acid. Such an acidulant may be added so that the food composition has a proper acidity for the purpose of inhibiting the growth of microorganisms other than the purpose of enhancing the taste.
본 발명의 건강 식품 조성물은 그 자체로도 건강식품으로 이용될 수 있고, 또는 상기 조성물을 식품 또는 음료 중에 포함할 수 있다. 본 발명의 조성물을 다른 식품 또는 음료에 포함시킬 경우에는 별도로 농축 과정이나, 분말화하는 과정을 추가하여 첨가하기 쉬운 형태로 만들어 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 각종 식품류, 예를 들어 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있으며, 환제, 분말, 과립, 침제, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The health food composition of the present invention can be used as health food itself, or it can be contained in food or beverage. When the composition of the present invention is contained in other foods or beverages, it may be added in a form that is easily added by adding a concentration process or a powdering process separately. Foods to which the composition of the present invention can be added include various foods such as beverages, gums, tea, vitamin complexes and health supplements, and they are in the form of pills, powders, granules, infusions, tablets, Can be used.
이하, 본 발명을 제조예 및 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Production Examples and Examples.
단, 하기 제조예 및 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 내용이 하기 제조예 및 실시예에 의해 한정되는 것은 아니다.However, the following Preparation Examples and Examples are for illustrating the present invention, and the content of the present invention is not limited by the following Production Examples and Examples.
<제조예 1> 당귀 추출물의 제조Preparation Example 1: Preparation of Angelica gigas Daiwai extract
당귀(Angelica gigas) 1kg에 대하여 중량 기준으로 정제수를 5~10배 되도록 넣은 후, 95℃에서 2~3시간 추출한 다음 저온에서 원심분리를 한 후 감압 농축하여 당귀 농축액 200~400g을 얻었다. To 1 kg of Angelica gigas , purified water was added 5 to 10 times by weight and then extracted at 95 ° C for 2 to 3 hours. The mixture was centrifuged at low temperature and concentrated under reduced pressure to obtain 200 to 400 g of Angelica gigas concentrate.
<제조예 2> 맥문동 추출물의 제조≪ Preparation Example 2 >
맥문동(Liriope muscari) 1kg에 대하여 중량 기준으로 정제수를 5~10배 되도록 넣은 후, 95℃에서 2~3시간 추출한 다음 저온에서 원심분리를 한 후 감압 농축하여 맥문동 농축액 200~400g을 얻었다. To 1kg of Liriope muscari , purified water was added 5 ~ 10 times by weight and then extracted at 95 ℃ for 2 ~ 3 hours. Then, it was centrifuged at low temperature and concentrated under reduced pressure to obtain 200 ~ 400g of concentrated liquid.
<제조예 3> 황기 추출물의 제조≪ Preparation Example 3 > Preparation of Hwanggi extract
황기(Astragalus membranaceus) 1kg에 대하여 중량 기준으로 정제수를 5~10배 되도록 넣은 후, 95℃에서 2~3시간 추출한 다음 저온에서 원심분리를 한 후 감압 농축하여 황기 농축액 200~400g을 얻었다. To 1kg of Astragalus membranaceus , purified water was added at a ratio of 5 to 10 times by weight, and then extracted at 95 ° C for 2 to 3 hours. The mixture was centrifuged at a low temperature and concentrated under reduced pressure to obtain 200~400 g of Hwanggi concentrate.
<제조예 4> 창이자 추출물의 제조≪ Preparation Example 4 >
창이자(Xanthium strumarium) 1kg에 대하여 중량 기준으로 정제수를 5~10배 되도록 넣은 후, 95℃에서 2~3시간 추출한 다음 저온에서 원심분리를 한 후 감압 농축하여 창이자 농축액 200~400g을 얻었다. To 1 kg of Xanthium strumarium , purified water was added 5 to 10 times by weight, and then extracted at 95 ° C for 2 to 3 hours. Then, the mixture was centrifuged at low temperature and concentrated under reduced pressure to obtain 200 ~ 400g of concentrated concentrate.
<제조예 5> 유근피 추출물의 제조≪ Preparation Example 5 >
유근피(느릅나무(Ulmus davidiana)의 뿌리) 1kg에 대하여 중량 기준으로 정제수를 5~10배 되도록 넣은 후, 95℃에서 2~3시간 추출한 다음 저온에서 원심분리를 한 후 감압 농축하여 유근피 농축액 200~400g을 얻었다. 1 kg of Ulmus davidiana was weighed 5 to 10 times as much as the weight of water and then extracted at 95 ° C for 2 to 3 hours. The mixture was centrifuged at a low temperature and then concentrated under reduced pressure to obtain 200 ~ 400 g was obtained.
<제조예 6> 홍삼 농축액의 제조≪ Preparation Example 6 > Preparation of red ginseng concentrate
홍삼 1kg에 대하여 중량 기준으로 정제수를 약 10배 되도록 넣은 후, 5~10회 70~90℃에서 추출한 다음 저온에서 원심분리를 한 후 감압 농축하여 홍삼 농축액 200~500g을 얻었다.To 1kg of red ginseng, purified water was added at a ratio of about 10 times by weight. The mixture was extracted 5 ~ 10 times at 70 ~ 90 ℃, centrifuged at low temperature and concentrated under reduced pressure to obtain 200 ~ 500g of red ginseng concentrate.
<제조예 7> 식물 혼합 농축액의 제조Preparation Example 7 Preparation of Plant Mixed Concentrate
제조예 1~5에서 수득한 각 추출물을 하기 표 1의 비율로 배합하여 식물 혼합 농축액을 제조하였다. Each of the extracts obtained in Production Examples 1 to 5 was blended in the ratio shown in Table 1 below to prepare a plant-mixed concentrate.
<제조예 8> 홍삼 및 식물 혼합 추출물을 포함하는 기관지 건강 개선용 조성물의 제조<Preparation Example 8> Preparation of composition for improving bronchial health including red ginseng and plant mixed extract
상기 제조예 5의 추출물 및 제조예 7의 식물 혼합 추출물로 기관지 건강 개선용 조성물을 하기 표 2의 비율로 제조하였다.The composition for improving bronchial health was prepared from the extract of Preparation Example 5 and the plant mixture extract of Preparation Example 7 at the ratios shown in Table 2 below.
<실시예 1> 기관지 개선 효과 확인 <Example 1> Confirmation of bronchodilating effect
제조예 8에서 제조한 조성물의 기관지 개선 효과를 확인하였다. 효과 확인 에는 총 120명이 참여하였으며, 각각 비흡연자 40명, 흡연자 40명, 노약자 40명이었다. 제조예 8의 조성물을 음용하기 전에 목과 기관지 등 호흡기 상태에 대한 설문지를 작성하였고, HUT(Home Usage Test) 방식으로 1포(50㎖)/1일 양으로 1개월간 음용하였다. 1개월 후에 동일한 설문지를 작성하여 목/기관지 등 호흡기 상태에 대한 개선 정도를 확인하였다. 설문 항목으로는 목의 답답함, 건조함, 칼칼함, 잠김 증상, 피로감, 목 감기, 목의 따끔거림, 편도(목) 부음, 기침(재채기), 가래 끓음, 면역 저하, 인후통, 목소리 갈라짐, 비염이었다. 각 항목에 대한 척도는 9점 척도로 하였고, 전반적인 목 건강 상태는 '1점: 전혀 좋지 않다' 내지 '9점: 매우 좋은 편이다'로 제시하여 복용 전/후의 개선 정도를 기록하였다(도 1의 '개선 정도' 항목, 도 4 내지 도 6의 '전반 목 건강 상태' 항목). 증상 개선율은 전체 응답자 중 Gap(복용 후/전)이 9점 척도 기준 1점 이상 상승한 응답자 비율을 나타낸다(도 1, 도 3 내지 6의 '개선율' 항목). 목/기관지 관련 증상 개선 정도는 '1점: 목/기관지 관련 증상이 전혀 없음' 내지 '9점: 목/기관지 관련 증상이 매우 많음'으로 제시하여 평가하였다(도 2, 도 4 내지 도 6의 '증상별 개선 정도' 항목). The bronchial improvement effect of the composition prepared in Preparation Example 8 was confirmed. A total of 120 participants participated in the confirmation of efficacy. There were 40 non - smokers, 40 smokers and 40 elderly people. Before drinking the composition of Preparation Example 8, a questionnaire about the respiratory condition such as the neck and bronchus was prepared and it was drunk for 1 month in the amount of 1 capsule (50 ml) per day by the HUT (Home Usage Test) method. After one month, the same questionnaire was written to confirm the improvement of respiratory condition such as neck / bronchus. The items of the questionnaire were stiffness of the neck, dryness, chalkiness, sleeping symptoms, fatigue, throat, neck tingling, one way (neck) panting, coughing (sneezing), sputum boiling, immune depression, sore throat, . Each item was scored on a 9-point scale, and overall neck health was rated as '1 point: Not at all good' to '9 points: Very good', and the degree of improvement before and after taking was recorded Item of improvement in health status " in FIGS. 4 to 6). The symptom improvement rate is the percentage of respondents who have risen more than one point on the 9 point scale after the Gap (after taking / taking) among the total respondents (the 'improvement rate' item in FIG. 1 and 3 to 6). The degree of neck / bronchial symptom improvement was evaluated as "1 point: no neck / bronchial related symptoms" to "9 points: very severe symptoms related to neck / bronchus" (FIG. 2, 'Improvement by symptom level' item).
제조예 8의 조성물을 1개월 동안 섭취한 결과, 전반적으로 설문 항목의 모든 증상이 완화되는 경향을 나타내었으며(도 1), 복용 전/후의 차이가 통계적으로 유의한 것으로 확인되었다(도 2). 도 2에 나타내는 바와 같이, 다른 항목에 비해서 목의 답답함, 건조함, 칼칼함, 잠김 항목은 다른 항목들에 비해서 특히 증상이 현저히 개선되는 것으로 나타났다. 또한, 전체 응답자 중에서 9점 척도를 기준으로 1점 이상 증상이 완화된 것으로 응답한 응답자 비율을 도 3에 나타낸다. 도 3에서 알 수 있듯이 제조예 8의 조성물은 목과 기관지에 대해서, 증상 완화 효과가 있고, 특히 목의 칼칼함, 답답함, 건조함에 대해서 개선 효과가 우수한 것을 알 수 있었다. As a result of ingestion of the composition of Preparation Example 8 for 1 month, all the symptoms of the questionnaire items tended to be alleviated (Fig. 1), and the difference before and after the administration was statistically significant (Fig. 2). As shown in FIG. 2, the items such as stiffness, dryness, dryness, and lockiness of the neck were significantly improved compared to other items, especially compared to other items. Figure 3 shows the percentage of respondents who answered that the symptom was alleviated by more than one point based on the 9 point scale among the total respondents. As can be seen from FIG. 3, the composition of Production Example 8 had a symptom-alleviating effect on the neck and bronchus, and it was found that the composition of the present invention had a particularly excellent improvement effect on the knitting, stiffness and dryness of the neck.
아울러, 효과 확인에 참여한 그룹인 비흡연자 40명, 흡연자 40명, 노약자 40명에 대해서도 개별적으로 각 설문 항목에 대한 증상을 확인하였다. 비흡연자의 경우 다른 항목에 비해서 목의 답답함, 칼칼함 항목에서 높은 개선율을 나타내었고(도 4), 흡연자군의 경우에는 목의 답답함, 건조함, 칼칼함, 따끔거림, 가래 끓음 증상에 대해서 개선 정도가 우수하였다(도 5). 흡연자에게서 많이 발생하는 목의 답답함, 건조함, 가래 끓음과 같은 기관지 증상이 제조예 8의 조성물을 섭취함으로써 개선되는 것을 알 수 있었다. 또한, 노약자의 군에 있어서는 목의 건조함, 피로감 증상이 개선되었다(도 6).In addition, symptoms of each questionnaire were individually identified for 40 non-smokers, 40 smokers, and 40 elderly people participating in the efficacy confirmation. The non-smokers showed a higher improvement rate in the frustration of the throat than in the other items (Fig. 4), and the degree of improvement in the smoother, drier, chewy, tingling and boiling (Fig. 5). It was found that the bronchial symptoms such as the frigidity, dryness, and boiling of the throat, which frequently occur in smokers, are improved by ingesting the composition of Production Example 8. In addition, dryness and fatigue symptoms of the neck were improved in the elderly group (Fig. 6).
이와 같은 결과로부터, 본 발명의 기관지 개선용 조성물이 목의 답답함, 건조함, 칼칼함을 비롯한 기관지에 나타나는 증상들을 완화하는 효과가 우수한 것을 알 수 있었다. From these results, it was found that the composition for improving bronchial condition of the present invention is excellent in relieving symptoms of bronchial asthma including dryness, dryness, and chalking.
<실시예 2> 맛 선호도 평가<Example 2> Evaluation of taste preference
기관지 증상 개선용 조성물에 대해서, 목 넘김의 부드러움, 화한 맛(시원한 맛), 쓴맛, 농도, 단맛, 홍삼 맛에 대해서 평가하였다. 평가 대상은 실시예 1의 대상과 동일하며, 5점 척도로 하여, '목 넘김의 부드러움' 항목에 대해서는 부드럽게 느껴질수록 높은 점수를 주었고, 다른 항목들에 대해서는 맛이 강할수록 높은 점수를 주었다. 평가 결과를 하기 표 3에 나타낸다.The compositions for improving bronchial symptoms were evaluated for softness of neck turn, sweet taste (cool taste), bitter taste, concentration, sweet taste and red ginseng taste. The subject of evaluation was the same as the subject of Example 1, and the score of "softness of neck turnover" was given higher score when it felt smooth, and the score of other items was higher when the taste was stronger. The evaluation results are shown in Table 3 below.
확인한 결과, 기관지 증상 개선용 조성물에 대한 전반적인 맛 호감도가 매우 높은 수준으로 나타났다. 선호 이유로는 쓴맛과 단맛이 적당하고, 홍삼 맛이 진하며, 맛이 시원하고, 맛이 부드럽다는 이유가 있으며, 적당한 쓴맛, 단맛과 조성물을 복용한 후에 느껴지는 화한(시원한) 느낌에 대한 선호가 호감도를 높게 평가하는데 긍정적으로 작용하였음을 알 수 있었다. As a result, the overall taste sensitivity of the compositions for improving bronchial symptoms was very high. The reason for preference is that bitterness and sweetness are appropriate, red ginseng taste is great, taste is cool, taste is soft, and favorable bitterness, sweetness and preference for sweet feeling after taking the composition are favorable It was found that they acted positively in the high evaluation.
실시예 1 및 실시예 2를 통하여, 본 발명의 기관지 증상 개선용 조성물이 목의 답답함, 건조함, 칼칼함을 비롯한 기관지 증상을 개선하면서도 맛에 대한 만족도가 높아 기관지 증상을 개선하는데 유용하게 사용할 수 있음을 알 수 있다.Through Examples 1 and 2, the composition for improving bronchopathy of the present invention can be used for improving bronchial symptoms by improving bronchial symptoms including dryness, dryness, and chalkiness while satisfying the taste. .
Claims (6)
상기 홍삼 추출물 1 내지 20중량부에 대해서, 당귀 추출물은 0.6 내지 0.1중량부로, 맥문동 추출물은 0.6 내지 0.1중량부로, 황기 추출물은 1.0 내지 0.3중량부로, 창이자 추출물은 0.6 내지 0.1중량부로, 유근피 추출물은 0.6 내지 0.1중량부로 포함되는 약학적 조성물.The method according to claim 1,
The extract of Angelica keiskei koidz. Extract is used in an amount of 0.6 to 0.1 parts by weight, the extract of Angelica keiskei koidzaiensis extract is used in an amount of 0.6 to 0.1 parts by weight, 0.6 to 0.1 part by weight.
호흡기 증상은 목의 답답함, 목의 건조함, 목의 칼칼함, 목 잠김 및 목의 따끔거림으로 이루어진 군으로부터 선택되는 어느 하나 이상인 약학적 조성물.The method according to claim 1,
Wherein the respiratory symptoms are selected from the group consisting of tightness of the neck, dryness of the neck, chalkiness of the neck, throat and neck tingling.
상기 홍삼 추출물 1 내지 20중량부에 대해서, 당귀 추출물은 0.6 내지 0.1중량부로, 맥문동 추출물은 0.6 내지 0.1중량부로, 황기 추출물은 1.0 내지 0.3중량부로, 창이자 추출물은 0.6 내지 0.1중량부로, 유근피 추출물은 0.6 내지 0.1중량부로 포함되는 건강 식품 조성물.The method of claim 4,
The extract of Angelica keiskei koidz. Extract is used in an amount of 0.6 to 0.1 parts by weight, the extract of Angelica keiskei koidzaiensis extract is used in an amount of 0.6 to 0.1 parts by weight, 0.6 to 0.1 part by weight.
호흡기 증상은 목의 답답함, 목의 건조함, 목의 칼칼함, 목 잠김 및 목의 따끔거림으로 이루어진 군으로부터 선택되는 어느 하나 이상인 건강 식품 조성물. The method of claim 4,
Wherein the respiratory symptoms are selected from the group consisting of stiffness of the neck, dryness of the neck, chalkiness of the neck, throat and neck tingling.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170016296A KR102134385B1 (en) | 2017-02-06 | 2017-02-06 | Composition for Respiratory Symptoms Containing Red Ginseng Extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170016296A KR102134385B1 (en) | 2017-02-06 | 2017-02-06 | Composition for Respiratory Symptoms Containing Red Ginseng Extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180091311A true KR20180091311A (en) | 2018-08-16 |
KR102134385B1 KR102134385B1 (en) | 2020-07-16 |
Family
ID=63443764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170016296A KR102134385B1 (en) | 2017-02-06 | 2017-02-06 | Composition for Respiratory Symptoms Containing Red Ginseng Extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102134385B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102297398B1 (en) | 2020-03-05 | 2021-09-02 | 김일웅 | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component |
KR102300766B1 (en) * | 2020-12-11 | 2021-09-13 | 유송미 | Composition of health functional beverage for improving rhinitis, removing sputum and improving respiratory disease |
KR20210117362A (en) | 2020-03-06 | 2021-09-29 | 김일웅 | Pharmaceutical and functional food composition comprising complex extract of Brassica rapa for prevention or treatment of respiratory disease |
KR20210117363A (en) | 2020-03-08 | 2021-09-29 | 김일웅 | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease |
KR20220094614A (en) * | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease |
KR20220094678A (en) * | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease by fine dust |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100847217B1 (en) * | 2007-03-21 | 2008-07-17 | 추금숙 | Healthy beverages for preventing and treating acute respiratory disease |
KR20100126898A (en) * | 2009-05-25 | 2010-12-03 | 청삼영농조합법인 | A composition of extracts made of ginsengsteamed red and omija, its health food, and preparation process of the same |
KR20130116500A (en) * | 2012-04-16 | 2013-10-24 | 김현정 | Korean medical compositions for improving rhinitis and empyema and the set |
KR101527483B1 (en) | 2007-03-05 | 2015-06-09 | 옴 파르마 에스아 | Bacterial extract for respitory disorders and process for its preparation |
-
2017
- 2017-02-06 KR KR1020170016296A patent/KR102134385B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101527483B1 (en) | 2007-03-05 | 2015-06-09 | 옴 파르마 에스아 | Bacterial extract for respitory disorders and process for its preparation |
KR100847217B1 (en) * | 2007-03-21 | 2008-07-17 | 추금숙 | Healthy beverages for preventing and treating acute respiratory disease |
KR20100126898A (en) * | 2009-05-25 | 2010-12-03 | 청삼영농조합법인 | A composition of extracts made of ginsengsteamed red and omija, its health food, and preparation process of the same |
KR20130116500A (en) * | 2012-04-16 | 2013-10-24 | 김현정 | Korean medical compositions for improving rhinitis and empyema and the set |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102297398B1 (en) | 2020-03-05 | 2021-09-02 | 김일웅 | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component |
KR20210117362A (en) | 2020-03-06 | 2021-09-29 | 김일웅 | Pharmaceutical and functional food composition comprising complex extract of Brassica rapa for prevention or treatment of respiratory disease |
KR20210117363A (en) | 2020-03-08 | 2021-09-29 | 김일웅 | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease |
KR102300766B1 (en) * | 2020-12-11 | 2021-09-13 | 유송미 | Composition of health functional beverage for improving rhinitis, removing sputum and improving respiratory disease |
KR20220094614A (en) * | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease |
KR20220094678A (en) * | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease by fine dust |
Also Published As
Publication number | Publication date |
---|---|
KR102134385B1 (en) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102134385B1 (en) | Composition for Respiratory Symptoms Containing Red Ginseng Extract | |
KR101498780B1 (en) | Composition for preventing or treating hangover | |
KR20010084854A (en) | Functional food containing extract of Platycodon grandiflorusjacqin A De Candolle and process and for preparation thereof | |
KR101054594B1 (en) | Liver Function Enhancer Composition | |
KR101615199B1 (en) | Functional compositions for relieving hangovers and protecting a liver, healthy food and food additive comprising the same | |
EP2436388A2 (en) | Composition for increasing the bioavailability of saponin | |
KR101181797B1 (en) | Method for Preparing Fermented Liquor of Epicarp of Ginkgo Biloba | |
WO2015046486A1 (en) | Anti-obesity composition | |
KR102169920B1 (en) | A composition comprising extract of Schisandra chinensis, pear and Platycodon grandiflorum for preventing or treating respiratory inflammatory diseases | |
KR20160144791A (en) | Composition for relieving menopausal symptom | |
KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
KR101103576B1 (en) | Composition for Removing Hangover and Composition for Improving Liver Function Using Bamboo Sprout and Bamboo Leaf | |
KR101897005B1 (en) | Composition for Relieving Hangover Using Ginsenoside Compound K | |
KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR102235563B1 (en) | Composition for fatigue recovery and sexual function improvement containing high content of arginine | |
KR102433586B1 (en) | Food composition for relieving hangover and improving hepatic function | |
KR20190001112A (en) | Anti-obesity composition comprising Protaetia brevitarsis seulensis larva extracts | |
KR102147592B1 (en) | Composition for rerpessing smoking and health functional food containing the composition | |
KR20210143967A (en) | Composition for preventing, improving or treating respiratory disease | |
KR101910823B1 (en) | Anti-stress Composition Using Ginsenoside Compound K | |
KR101711397B1 (en) | Pharmaceutical compositions and health functional foods comprising Persicaria fauriei extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
KR20130029283A (en) | Composition for constipation | |
KR20180006612A (en) | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof | |
KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |